MIR1249 and neoplasm: When assessed by in situ hybridization (ISH), MIR1249 was strongly positive in 53% of the tumor cases and was statistically associated with lower survival outcome (cohort 3, n = 28) (Fig. 1D‐E and Supporting Table S3).